Gapping up
In reaction to strong earnings/guidance:
- GOOS +18.1%, SCHN +3.2%, JBL +1.7%
M&A news:
- NXPI +2.4% (following reports of MOFCOM approval of NXPI / QCOM deal), QCOM +1.2%
- TWX +1.7% (DOJ cleared AT&T deal)
Other news:
- VSTM +11.8% (announced a registered sale to funds managed by Consonance Capital of 7,166,666 shares of the Company's common stock at a price of $6.00/share), RDY +6% (receives FDA approval for launch of Buprenorphine and Naloxone Sublingual Film in US)
- HUYA +4.1% (recent IPO seeing continued momentum after today's 13% move to new all time highs)
- MFIN +3.1% (Key Colony discloses 5.26% active stake)
- IQ +2.8% (extending today's 17% move higher)
- SRNE +2.1% (indicated higher after releasing Chairman/CEO letter with corp update - says evaluating strategic partnerships for some of assets in development)
- BLUE +2.1% (reports new Data from Northstar studies of LentiGlobin)
- DDR +1.2% (files mixed securities shelf offering)
- MYL +1% (FDA approved first generic versions of Suboxone (buprenorphine and naloxone) sublingual film (applied under the tongue) for the treatment of opioid dependence)
Analyst comments:
- TXMD +4.5% (initiated with a Overweight at JP Morgan)
- AMD +1.3% (target raised to $21 at Cowen)
- HDP +1.1% (initiated with Buy rating at Nomura Instinet)
